Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Trial Profile

Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Vonapanitase (Primary)
  • Indications Thrombosis; Vascular disorders
  • Focus Adverse reactions; Registrational
  • Acronyms PATENCY-1
  • Sponsors Proteon Therapeutics
  • Most Recent Events

    • 07 Aug 2017 According to a Proteon Therapeutics media release, results from this study will be presented at the Vascular Access Society of Britain and Ireland Conference in September 28-29.
    • 10 May 2017 According to a Proteon Therapeutics media release, vonapanitase has received Breakthrough Therapy designation from the US FDA for increasing arteriovenous fistula secondary patency (i.e., survival of the fistula without abandonment) and use for hemodialysis in patients on or expected to initiate hemodialysis. The Breakthrough Therapy designation is supported by data from this trial.
    • 10 May 2017 Results from this trial were presented at the Charing Cross Symposium (CX 2017), according to a Proteon Therapeutics media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top